Cegedim S.A. (0DYQ.L) stock: Winston Score, insiders and Congress trades
Cegedim is a French technology and services company that builds software and tools for the healthcare industry. Its main products include practice management software for doctors and pharmacists, digital health platforms, and data analytics services sold to pharmaceutical companies. It has been operating in this space for over 50 years, making it one of the more established healthcare IT providers in Europe. Cegedim earns money primarily through software subscriptions, licensing fees, and data services rather than selling physical products, which explains its very high gross margin. The company operates mainly in France but also has a presence in the United Kingdom, Romania, and other European markets, with roughly 6,000 employees. Its long-standing relationships with healthcare professionals and proprietary patient and prescription data give it some stickiness with customers, but its very thin operating margin of under 2% signals that costs are high relative to revenue, and the key risk is whether it can scale efficiently enough to meaningfully improve profitability.
Winston Score: 33 out of 100, Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Weak (5/30)
- Growth: Weak (3/20)
- Cash Flow: Exceptional (9/10)
- Stability: Mixed (3/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: 10.90 GBp
Market Cap: £150M
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Exchange: London Stock Exchange
Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-04.



